Pharmacokinetics and Safety of Tazemetostat in Hepatic Impairment With Advanced Malignancies

Phase 1, open-label, single-arm trial of tazemetostat in advanced malignant solid tumor and hematological malignancy, sponsored by Epizyme, Inc. Primary endpoints: Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration at 72 hours, Area under the plasma concentration-time curve from time 0 extrapolated to infinity at 72 hours and 5 more. Started Jan 2020; status: terminated.